Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia
Autore:
Junquera, F; Feu, F; Papo, M; Videla, S; Armengol, JR; Bordas, JM; Saperas, E; Pique, JM; Malagelada, JR;
Indirizzi:
Autonomous Univ Barcelona, Hosp Gen Valle Hebron, Digest Syst Res Unit, E-08193 Barcelona, Spain Autonomous Univ Barcelona Barcelona Spain E-08193 08193 Barcelona, Spain Univ Rovira & Virgili, Hosp Joan XXIII, Gastroenterol Sect, Tarragona, Spain Univ Rovira & Virgili Tarragona Spain troenterol Sect, Tarragona, Spain
Titolo Testata:
GASTROENTEROLOGY
fascicolo: 5, volume: 121, anno: 2001,
pagine: 1073 - 1079
SICI:
0016-5085(200111)121:5<1073:AMRCTO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESTROGEN-PROGESTERONE THERAPY; HEREDITARY HEMORRHAGIC TELANGIECTASIA; CHRONIC RENAL-FAILURE; PROGESTAGEN TREATMENT; NATURAL-HISTORY; COLON; RATS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Pique, JM Hosp Clin Barcelona, Dept Gastroenterol, Inst Malalties Digest, Villarroel170, E-08036 Barcelona, Spain Hosp Clin Barcelona Villarroel 170 Barcelona Spain E-08036 pain
Citazione:
F. Junquera et al., "A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia", GASTROENTY, 121(5), 2001, pp. 1073-1079

Abstract

Background & Aims: The efficacy of hormonal therapy for recurrent bleedingfrom gastrointestinal angiodysplasia remains uncertain. We investigated the efficacy of long-term estrogen-progestagen therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Methods: Seventy-two noncirrhotic patients bleeding from gastrointestinal angiodysplasia confirmed by endoscopy or angiography were randomized to receive in double-blind conditions treatment with ethinylestradiol (0.01 mg) plus norethisterone (2 mg) (1tablet/d), or placebo (I tablet/d) for a minimum period of 1 year (range: 1-2 years). Results: Four patients could not be assessed because they did not attend the first follow-up visit. Failure of treatment occurred in 13 of33 (39%) patients in the treatment group and in :16 of 35 (46%) patients in the placebo group (P = NS). No significant differences between groups were found according to number of bleeding episodes (0.7 +/- 1.0 vs. 0.9 +/-1.5) and transfusional requirements (0.9 +/- 1.9 vs. 0.7 +/- 1.5 units). Treatment received was not an independent predictor for rebleeding prevention in the multivariate regression analysis. Severe adverse events (2 vs. 1) andmortality (0 vs. :1 patient, respectively) were similar between the treatment and placebo groups. Conclusions: Continuous estrogen-progestagen treatment is not useful in the prevention of rebleeding from gastrointestinal angiodysplasia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 22:02:10